5fqv: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 5.== | ==Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 5.== | ||
<StructureSection load='5fqv' size='340' side='right' caption='[[5fqv]], [[Resolution|resolution]] 1.74Å' scene=''> | <StructureSection load='5fqv' size='340' side='right'caption='[[5fqv]], [[Resolution|resolution]] 1.74Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[5fqv]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FQV OCA]. For a <b>guided tour on the structure components</b> use [http:// | <table><tr><td colspan='2'>[[5fqv]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FQV OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5FQV FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=VQI:(E)-3-[4-(6-HYDROXY-2-ISOBUTYL-7-METHYL-3,4-DIHYDRO-1H-ISOQUINOLIN-1-YL)PHENYL]PROP-2-ENOIC+ACID'>VQI</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=VQI:(E)-3-[4-(6-HYDROXY-2-ISOBUTYL-7-METHYL-3,4-DIHYDRO-1H-ISOQUINOLIN-1-YL)PHENYL]PROP-2-ENOIC+ACID'>VQI</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5fqp|5fqp]], [[5fqr|5fqr]], [[5fqs|5fqs]], [[5fqt|5fqt]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5fqp|5fqp]], [[5fqr|5fqr]], [[5fqs|5fqs]], [[5fqt|5fqt]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http:// | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5fqv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fqv OCA], [http://pdbe.org/5fqv PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5fqv RCSB], [http://www.ebi.ac.uk/pdbsum/5fqv PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5fqv ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
| Line 19: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 5fqv" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 5fqv" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Estrogen receptor 3D structures|Estrogen receptor 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Large Structures]] | |||
[[Category: Davies, R D.M]] | [[Category: Davies, R D.M]] | ||
[[Category: Degorce, S L]] | [[Category: Degorce, S L]] | ||
Revision as of 10:32, 6 May 2020
Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 5.Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 5.
Structural highlights
Function[ESR1_HUMAN] Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1.[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Publication Abstract from PubMedA series of tetrahydroisoquinoline phenols was modified to give an estrogen receptor downregulator-antagonist profile. Optimization around the core, alkyl side chain, and pendant aryl ring resulted in compounds with subnanomolar levels of potency. The phenol functionality was shown to be required to achieve highly potent compounds, but unusually this was compatible with obtaining high oral bioavailabilities in rat. Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat.,Scott JS, Bailey A, Davies RD, Degorce SL, MacFaul PA, Gingell H, Moss T, Norman RA, Pink JH, Rabow AA, Roberts B, Smith PD ACS Med Chem Lett. 2015 Dec 19;7(1):94-9. doi: 10.1021/acsmedchemlett.5b00413., eCollection 2016 Jan 14. PMID:26819673[19] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||